Fresenius received a voluntary medwatch (mw5145376) report stating that a hemodialysis (hd) patient utilizing an optiflux f180nre dialyzer began complaining of nausea, vomiting, diarrhea, abdominal pain, chest tightness, and flushing within minutes of hd treatment initiation.Additional information was obtained through follow-up with the clinical nurse manager.The patient arrived for a regularly scheduled four-hour hd treatment.The patient¿s treatment was initiated at 1200 hours.Within the first minute of treatment start, the patient complained of nausea, vomiting, diarrhea, abdominal pain, chest tightness, and flushing.The treatment was discontinued, and time noted at 1200 hours.The patient¿s blood was not rinsed back, and the estimated blood loss was 100ml.The patient was administered ondansetron 4mg intravenous push (ivp) and diphenhydramine 50mg ivp.The patient recovered on site and was discharged home in stable condition.The patient resumed treatment on a subsequent date with an optiflux f180nr dialyzer without incident.The f180nre dialyzer was added as an allergy to the patient¿s medical history.This event was classified as a dialyzer reaction.The patient does not require any additional pre-treatment medication with the f180nr dialyzer.The dialyzer is to be flushed with saline per protocol.No sample was expected to be returned for evaluation.
|
Clinical investigation: based on the available information, there is a temporal and likely causal relationship between the fresenius opitflux f180nre dialyzer and the patient¿s reaction (characterized by nausea, vomiting, diarrhea, abdominal pain, chest tightness, and flushing).Although rare, hypersensitivity or anaphylactoid reactions to dialyzers are a known risk during hemodialysis.The exposure of the patient¿s blood to a foreign substance present in the extracorporeal circuit is the result of an immunoallergic response.Type a reactions usually begin in the first few minutes of dialysis and are associated with symptoms such as itching, burning sensation at the access site, urticaria, flushing, cough, sneezing, wheezing, abdominal cramps, diarrhea, headache, back and chest pain, nausea, vomiting, fever, and chills.Although the patient experienced an adverse reaction during treatment, there is no allegation of a product malfunction or deficiency related to this event.Plant investigation: no sample was returned for manufacturer evaluation.A production records review was performed on the reported lot.An investigation of the device history records (dhr) was conducted by the manufacturer.There was no indication of product nonacceptance, deviation, non-conformance, rework, labeling or process control failure during the manufacturing process which could be associated with the reported event.The lot met all release criteria.A definitive conclusion regarding the complaint incident cannot be reached with the information provided.Therefore, the complaint was not confirmed.
|